Adversity and resilience in Rossana Zaera and Teresa Cebrián’s work

[ES] La adversidad como infortunio ha formado parte de la inevitable existencia del ser humano, quien experimentándola en la propia piel ha tomado consciencia del mundo que le rodea. Estas experiencias han formado parte de la metamorfosis corporal y han servido de aprendizaje. Una información de carácter individual que puesta en común ha ayudado en la creación de conocimiento. Experiencias adversas como el dolor, la muerte, la enfermedad, el sufrimiento y su impacto en el tiempo, han sido motivo de reflexión y motor de creación para artistas como Rossana Zaera y Teresa Cebrián –sobre las que centraremos el artículo- o artistas como Natividad Navalón, Francisca Lita o Ángeles Marco. Artistas que, tratando en su obra temas de carácter transcultural para el individuo, han canalizado su propia vivencia de la realidad que las rodea. Su reflexión e investigación han permitido indagar en la oscura realidad que atormenta al ser humano, sus inquietudes y su amplia posibilidad de representación artística. [EN] Adversity as misfortune has been a part of the inevitable existence of the human being, who, in experimenting such misfortune in their own flesh, has become aware of the world around them. These experiences, which always imply a learning process, sometimes also involve an individual’s bodily metamorphosis. An information and/or deformation which conditions life and thought. To us, furthermore, this becomes a nucleus for reflection, analysis, and transmission of knowledge. Likewise, as creatives, this allows us to develop our craft as a means of introspection, meditation, and appropriation of our experience. Adverse experiences such as pain, death, illness, suffering, and their impact on time have been a reason for reflection and creative fuel for contemporary artists within the national and international panorama. In this article, which is developed within our line of research concerning art and illness, we will focus on an analysis of the works of Rossana Zaera and Teresa Cebrián. These two artists, who, in dealing themes of transcultural character for the individual, have channeled their own experience of reality which surrounds them through artistic creation. Their reflection and investigation have allowed them to delve into the dark reality which torments the human being and to transmit their concerns through the width of possibilities their artistic representation grants.Gil Gil, C.; Barón Linares, V.; Soto Navalón, NAD.; Cháfer Bixquert, T. (2020). Adversidad y resiliencia como recurso en la creación artística de Rossana Zaera y Teresa Cebrián. ANIAV - Revista de Investigación en Artes Visuales. 0(7):63-82. https://doi.org/10.4995/aniav.2020.12983OJS638207Anzieu, D. (2007). El Yo Piel. Madrid: Biblioteca NuevaCarrión, I. (2005, diciembre, 18). La estética del dolor. El País. Recuperado 22 junio 2018, de https://elpais.com/diario/2005/12/18/cvalenciana/1134937100_850215.htmlCastillo, A. (1999). El dolor a través de la historia del arte. Madrid: Sanofi WinthropConsorci de Museus de la Comunitat Valenciana. (2018). Teresa Cebrián: El Largo Viaje. Valencia: Consorci de Museus de la Comunitat ValencianaConsorci de Museus de la Comunitat Valenciana. (1999). Teresa Cebrián. Del silencio de las lágrimas: Sala La Gallera 20‐XII, 1999 / 30‐I, 2000. Valencia: Consorci de Museus de la Comunitat ValencianaForés, A. Grané, J. (2008). La resiliencia. Crecer desde la adversidad. Barcelona: Plataforma EditorialGeneralitat Valenciana. (1998). Mar de Fondo. Valencia: Direcció General de Promoció Cultural, Museus i Belles Arts: Universidad de ValenciaGras, I. (2017). Rossana Zaera. Resiliencia Artística. Dossiers Feministes, 21, 59‐74 https://doi.org/10.6035/Dossiers.2016.21.4Moscoso, J. (2004). Una historia del Dolor. Claves de razón práctica, 139, 34‐40IVAM Institut Valencià d'Art Modern. (2018) Ángeles Marco; Vértigo. Valencia: IVAM. Institut Valencià d'Art ModernIVAM Institut Valencià d'Art Modern. (2009). Natividad Navalón: la maleta de mi madre. Valencia: IVAM. Institut Valencià d'Art ModernOcaña, E. (1997). Sobre el dolor. Valencia: Pre‐TextosPanadero, A. (2007, octubre, 14). Rossana Zaera Clausell: Almagrafías de una vida, de un paseo por las luces y las sombras. El Periódico Mediterráneo. Recuperado 23 octubre 2019, de https://www.elperiodicomediterraneo.com/noticias/rossana‐zaeraclausell‐almagrafias‐vida‐paseo‐luces‐sombras_329430.htmlTeófila, Mª T., Lita, F., Montes, M. (2008). La Migraña. Ciencia, arte y literatura. Bilbao: LetteraUniversitat Jaume I. (2018). De FEMÍNEO. Un art sense límits. Castelló: Servei de Comunicació i Publicacions. Universitat Jaume IRojas, L. (2010). Superar la adversidad. El poder de la resiliencia. Barcelona: EspasaZaera, R. (2011). Memoria de la vida. Madrid: OrfilaZaera, R. (2014). Humanas, demasiado Humanas [Las heridas del Alfabeto natural]. Palma de Mallorca: Lluc Fluxà. Espai H.CREFERENCIAS EN LÍNEA:Ciges, T. (2015). Rossana Zaera: «La intuición que guía al artista es la misma que guía al científico». Recuperado 20 octubre 2019, de https://metode.es/noticias/entrevistas/rossana‐zaera‐la‐intuicion‐que‐guia‐al‐artistaes‐la‐misma‐que‐guia‐al‐cientifico.htmlCentre del Carme Cultura Contemporània. (2018). El Centre del Carme reivindica la obra de la escultora valenciana Teresa Cebrián. Recuperado 20 julio 2018, de https://www.consorcimuseus.gva.es/centro‐del‐carmen/prensa/el‐centre‐del‐carmereivindica‐la‐obra‐de‐la‐escultora‐valenciana‐teresa‐cebrian/?lang=esZaera, R. (s.f). Recuperado de https://www.rossanazaera.coms

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH